The science of
weight loss,
redefined.
Grounded in clinical research and FDA-approved breakthroughs, we target the biological roots of metabolic health with precision.
SURMOUNT-1 Trial
Pivotal phase 3 clinical trial demonstrating the efficacy of Tirzepatide in weight reduction.
20.9%
Reduction
Avg. Body Weight
FDA Approved 2023
Care that works
with your biology.
Modern GLP-1 medications mimic natural hormones but with extended durability, providing consistent metabolic signals.
Appetite Regulation
GLP-1 targets the hypothalamus in the brain to increase feelings of fullness and reduce food cravings.
Slower Digestion
It slows gastric emptying, which helps you feel fuller for longer after eating smaller portions.
Metabolic Health
Improves insulin sensitivity and helps the body process glucose more efficiently.
Molecularly designed for sustained metabolic support.
Validated by landmark
clinical trials.
Our clinical protocols are rooted in large-scale, double-blind, placebo-controlled studies published in the world's leading medical journals.
STEP 1 Clinical Trial
Semaglutide 2.4mg
Mean body weight loss over 68 weeks
Significant reduction compared to 2.4% for placebo group.
SURMOUNT-1 Trial
Tirzepatide 15mg
Mean body weight loss over 72 weeks
Significant reduction compared to 3.1% for placebo group.
Note: Individual results vary. Treatment is subject to clinical review.
FDA Approval Timeline
Ozempic® (Semaglutide) Approval
FDA approved for the treatment of type 2 diabetes.
Wegovy® (Semaglutide) Approval
FDA approved specifically for chronic weight management.
Mounjaro® (Tirzepatide) Approval
Dual GIP and GLP-1 receptor agonist approved for diabetes.
Zepbound® (Tirzepatide) Approval
FDA approved Tirzepatide for chronic weight management.
Academic References
New England Journal of Medicine, 2021
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, et al.
New England Journal of Medicine, 2022
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, et al.
Nature Medicine, 2022
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT, et al.
Backed by science, led by doctors.
Take the clinical route to sustainable weight loss.